
The acquisition brings Gallant’s experimental stem cell treatments for feline chronic gingivostomatitis and osteoarthritis in dogs and cats into Dechra’s portfolio.
Here's a sneak peek of this week's headlines.
As you enjoy these final few weeks of summer, we remain dedicated to providing you with a robust mix of industry hot topics and engaging news.
Here are some headlines to expect this week:
Stay tuned on dvm360.com and our social media channels for our latest coverage of the veterinary industry.





